Oncomatryx Biopharma has secured €12.5 million in funding from the European Innovation Council (EIC) Accelerator under the EU's Horizon Europe 2021-2027 Research and Innovation Program, positioning the Spanish biotechnology company to advance its next-generation antibody-drug conjugate (ADC) platform for oncology applications.
The highly competitive EIC Accelerator program attracted 959 applications from across 16 countries, with only 40 companies selected for funding. Oncomatryx stands as the sole oncology company among this distinguished group, receiving €2.5 million in grant funding alongside a €10 million equity investment commitment for its upcoming financing round.
Clinical Progress with OMTX705
Oncomatryx is advancing its lead ADC candidate, OMTX705, which targets Fibroblast Activation Protein (FAP) in aggressive tumors with high unmet medical need. Clinical data presented at the ASCO 2025 meeting demonstrated encouraging results from the dose escalation and backfilling cohorts.
The Phase I trial treated 95 patients across dose escalation and three backfilling cohorts of metastatic immune-cold solid tumors. The study revealed an outstanding safety profile with no dose-limiting toxicity observed, while patients expressing FAP showed long-duration responses to treatment.
"This funding will enable us to advance the expansion cohorts of our ongoing Phase I clinical trial in pancreatic, colorectal, and lung cancer, following highly promising results in the dose-escalation phase," said Laureano Simón, CEO of Oncomatryx.
Advancing Randomized Trials
Building on the promising Phase I results, Oncomatryx is currently conducting randomized clinical trials targeting immune-cold metastatic pancreatic cancer, microsatellite stable (MSS) colorectal cancer, and non-small cell lung cancer. These trials represent a significant advancement in addressing hard-to-treat solid tumors with limited therapeutic options.
Proprietary ADC Platform
Oncomatryx's unique ADC platform integrates proprietary novel payloads with advanced conjugation formats. The company operates fully integrated research and development, chemistry, and conjugation facilities, establishing itself as Europe's most advanced ADC development platform spanning from discovery through clinical-stage development.
The company's approach combines deep understanding of tumor microenvironment biology with proprietary payloads and linker technologies, positioning Oncomatryx as a strategic leader in oncology innovation.
Strategic Recognition and Support
Beyond the EIC Accelerator award, Oncomatryx has received strategic company designation from both the Government of Spain and the Basque Regional Government. The Spanish government's R&D funding body, CDTI, through its Innvierte co-investment initiative for strategic companies, and the Basque Regional Government have both invested directly in the company.
"Securing EIC Accelerator funding is a major milestone for Oncomatryx and a strong validation of our innovative approach to oncology drug development," Simón stated. "We are honored to be recognized as Europe's leading ADC platform and contribute to advancing new treatment options for patients with hard-to-treat solid tumors."
These endorsements collectively position Oncomatryx as a leading European player in oncology and the ADC field, with the funding enabling continued advancement of its clinical programs targeting some of the most challenging cancer types.
